Alexion’s Ultomiris Fails to Meet Primary Endpoint in Phase III HSCT-TMA Trial Despite Showing Treatment Benefit Trend
Alexion, AstraZeneca plc’s (NYSE: AZN) rare disease unit, announced top-line results from its Phase III...
Alexion
AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer
AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...